PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877426
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877426
The Therapeutic Apheresis Market size was valued at US$ 2,879.23 Million in 2024, expanding at a CAGR of 4.1% from 2025 to 2032.
Therapeutic apheresis is a medical procedure that involves drawing blood from a patient, processing it to remove specific components, and then returning it to the body. The Therapeutic Apheresis market is primarily driven by the growing global burden of autoimmune and neurological disorders, which is increasing clinical demand for plasma exchange and other procedures. The growing use of apheresis in advanced cell therapies, particularly CAR-T and stem-cell treatments, presents a significant opportunity for device manufacturers and service providers to generate new revenue streams. However, market growth is constrained by the high cost of equipment and procedures, preventing widespread adoption in low- and middle-income countries. The market is being shaped by a rapid shift toward automated, AI-enabled apheresis systems designed to improve patient outcomes, reduce procedure time, and increase safety.
Therapeutic Apheresis Market- Market Dynamics
Rise In Chronic Conditions Is Anticipated To Fuel The Market Growth
The rise in chronic conditions is expected to drive the apheresis consumables and equipment market forward. Chronic conditions, also known as chronic diseases, are long-term health conditions that persist for an extended period of time, often for the rest of a person's life, and are typically incurable. Apheresis consumables and equipment are critical for managing chronic diseases because they allow for the targeted removal or collection of blood components in conditions such as autoimmune disorders, familial hypercholesterolemia, sickle cell disease, and stem cell harvest. For instance, the National Library of Medicine, a government medical library based in the United States, predicts that by 2035, nearly 36% of US adults aged 50 and older will have at least one chronic condition, with that figure expected to rise to nearly 48% by 2050. As a result, the rise in chronic conditions is propelling the apheresis consumables and equipment market.
The worldwide market is segmented on the basis of Technology, Procedure Type, End User, Application, Component, and Region.
The component segmentation, which comprises five major groups, Plasmapheresis, LDL Apheresis, Leukapheresis, Photopheresis, and Others. Among this, plasmapheresis accounted for a significant share of the Global Apheresis Market. Its strong position is supported by the rising prevalence of autoimmune and neurological disorders, driven by genetic predispositions and shifting lifestyle patterns. According to the Multiple Sclerosis International Federation, the number of people living with Multiple Sclerosis increased from 2.8 million in 2020 to 2.9 million in 2023, highlighting the expanding population requiring therapeutic interventions. Plasmapheresis plays a vital role in managing such conditions by removing inflammatory agents, autoantibodies, and other damaging substances from the bloodstream, leading to reduced severity and duration of disease relapses. As a result, healthcare professionals are increasingly recommending this procedure as part of treatment strategies, contributing to the continued growth of the plasmapheresis segment.
Based on End-User segment, Blood banks are one of the most visible and highly utilized segments in the Therapeutic Apheresis Market, owing to their critical role in collecting, processing, and supplying blood components required for therapeutic and emergency medical purposes. These facilities routinely perform apheresis procedures, such as plasmapheresis, plateletpheresis, and leukapheresis, to ensure the availability of specialized blood components for patients suffering from autoimmune, oncological, and hematological diseases. Their established infrastructure, standardized operating protocols, and high donor throughput allow them to meet the steady demand for advanced apheresis systems and consumables. The segment's importance is bolstered by ongoing efforts to increase donor engagement and strengthen blood collection capacity. For instance, in 2023, a new blood collection center was opened at Singapore's One Punggol integrated community hub to meet rising demand and encourage increased donor participation, particularly among young people. Such developments highlight the growing emphasis on establishing strong blood-collection networks, emphasizing why blood banks remain an important and rapidly expanding component of the therapeutic apheresis landscape.
Therapeutic Apheresis Market- Geographical Insights
North America holds a prominent market share in the global apheresis market. Chronic diseases are common in North American countries, and there is a large patient population suffering from hematological diseases. For instance, the Global Cancer Observatory estimates that approximately 71.7 thousand new cases of leukemia will be reported in North America in 2022. Similarly, the Centers for Disease Control and Prevention (CDC) reported in 2023 that sickle cell disease (SCD) affects approximately 100,000 Americans. This necessitates the need for the best therapeutic solutions, which drives the North American Apheresis Market. Furthermore, the per capita consumption in these countries is increasing, resulting in significant growth in health expenditure. Individuals are increasingly opting for advanced therapies as economic growth accelerates, boosting market growth.
United States Therapeutic Apheresis Market- Country Insights
The United States is the region's major market. The increasing geriatric population in the United States is driving market growth. As the population ages, more cancer cases and chronic diseases are likely to emerge. This factor will help to drive regional market growth. The growing burden of blood-related ailments such as kidney disease, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels are the primary factors driving the growth of the studied market in North America. According to the Leukemia & Lymphoma Society (LLS), someone in the United States is diagnosed with blood cancer every three minutes. Approximately 178,520 people in the United States were diagnosed with leukemia, lymphoma, or myeloma in 2020. Leukemia, lymphoma, and myeloma accounted for 9.8% of the 1,898,160 new cancer cases diagnosed in the United States in 2021. As a result, the high incidence of target diseases drives the market's growth.
The therapeutic apheresis market has a moderately consolidated competitive environment, with innovation, technology integration, and procedural efficiency playing important roles in differentiation. Companies in this space compete primarily by developing advanced apheresis systems that provide increased automation, improved safety profiles, and shorter procedure times. Consumables, service contracts, and training programs are critical components of competitive strategy, as healthcare facilities increasingly prefer vendors who provide comprehensive operational support. Market participants are also focusing on expanding indications, such as autoimmune, neurological, and cell-therapy applications, to increase clinical relevance and adoption. Regulatory approvals, evidence-based clinical data, and integration with digital monitoring platforms help to define competitive advantages.
In August 2023, TERUMO BCT, INC received FDA approval for a groundbreaking platelet device that converts blood into platelets in a single centrifugation cycle, increasing the speed and reliability of blood component preparation.
In August 2023, Fresenius Kabi AG and Lupagen Inc. have signed a new supply and development agreement. This collaboration focuses on developing technologies to improve the delivery of cell and gene therapies directly to patients in clinical settings.